Connect with us


Trump vs Biden: Betting Markets Give Round 2 to Donald says Cloudbet


U.S. President Donald Trump won support from the betting public with a more measured and articulate performance in his second debate against Joe Biden, who was also facing fresh controversy over alleged foreign business dealings.

Odds on a Trump win improved to 2.6 (or 160) immediately after the debate, meaning betting markets give him a 38.5% chance of being elected, according to prices compiled by crypto sportsbook Cloudbet. That compares to 2.76 (36%) just before the debate. While Biden is still favored, his odds drifted to 1.54 (or -185) from 1.48.

Cloudbet saw thousands of dollars of fresh wagers – amounting to 5% of the books total US election exposures – come in for Trump following the event. In the past 7 days, 94% of the value of election-related bets at Cloudbet has been on the current president.

People still remember 2016. At the time, the odds heavily favored Clinton, but Trump defied the odds then and some people think he could do it again.

Cloudbet is tracking the two candidates price movements closely as part of its comprehensive politics offering that allows customers to bet on the election winner as well as on state-by-state outcomes. The operators politics page features a superbly designed electoral college map integration that gives users an instant opinion on which party is likely to win the election, based on real-time odds presented for each state.

The election map significantly amplifies whats on offer at Cloudbet for players seeking the best odds for bitcoin politics betting from the comfort of their homes or on the go. Founded in 2013, Cloudbet is one of the worlds longest established bitcoin operators, which relaunched its website in April with bold new features such as esports and credit-card coin purchases to attract a more diverse audience.

The site also accepts ethereum, bitcoin cash, USDT, USDC and Pax Gold, the last of which was launched just last week on Cloudbet.

Follow us on Twitter for latest news and promotions: @Cloudbet

For more information contact

Camilla Wright

[email protected]


Global Point of Care Diagnostics Market Growth Momentum to Reduce During 2020-2024 | Technavio


The point of care diagnostics market is poised to grow by USD 10.69 billion during 2020-2024, decelerating at a CAGR of over 10% during the forecast period.

Worried about the impact of COVID-19 on your Business? Here is an Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.

Get FREE Sample Report in Minutes!

The report on the point of care diagnostics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the growing geriatric population.

The point of care diagnostics market analysis includes the product, end-user, and geography landscape. This study identifies the shift from conventional testing methods to rapid diagnostics as one of the prime reasons driving the point of care diagnostics market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The point of care diagnostics market covers the following areas:

Point Of Care Diagnostics Market Sizing

Point Of Care Diagnostics Market Forecast

Point Of Care Diagnostics Market Analysis

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • PerkinElmer Inc.
  • PTS Diagnostics
  • Sekisui Chemical Co. Ltd.
  • Siemens Healthineers AG
  • Trinity Biotech Plc


Related Reports on Health Care Include:

Global Point-of-Care Coagulation Testing Market – Global point-of-care coagulation testing market is segmented by end-user (Hospitals and clinics and Homecare) and geographic landscape (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Global Molecular Point of Care Devices Market – Global molecular point of care devices market is segmented by application (infectious diseases, oncology, and others) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Hematology diagnostics – Market size and forecast 2019-2024
  • Infectious disease diagnostics – Market size and forecast 2019-2024
  • Rapid cardiovascular diagnostics – Market size and forecast 2019-2024
  • Rapid coagulation diagnostics – Market size and forecast 2019-2024
  • Others – Market size and forecast 2019-2024
  • Market opportunity by Product

Market Segmentation by End-user

  • Market segments
  • Comparison by End-user
  • Hospitals and clinics – Market size and forecast 2019-2024
  • Homecare settings – Market size and forecast 2019-2024
  • Clinical diagnostic laboratories – Market size and forecast 2019-2024
  • Market opportunity by End-user

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2019-2024
  • Europe – Market size and forecast 2019-2024
  • Asia – Market size and forecast 2019-2024
  • ROW – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers “ Demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • PerkinElmer Inc.
  • PTS Diagnostics
  • Sekisui Chemical Co. Ltd.
  • Siemens Healthineers AG
  • Trinity Biotech Plc


  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]


Continue Reading


Khiron Reports Third Quarter 2020 Financial Results

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia. Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia, simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020, selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia, extending education and sales reach further across the country
  • As a result of the Company's Doctor ZereniaTM telehealth platform more than 25% of the Company's medical cannabis prescriptions came from outside of Bogota, expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru. Additional approval received from Peru's drug regulatory authority for Company's High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America's largest home multi-vertical app platform to distribute the Company's CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company's KuidaTM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

TORONTO, Nov. 30, 2020 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today its financial results for the quarter ended September 30, 2020. These filings are available for review on the Company's SEDAR profile at All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Summary of Key Quarterly Financial Results

Canadian dollars

3 Months
ended Sept
30 2020

3 Months
Ended Sept 30

9 Months
ended Sept
30 2020

9 Months
Ended Sept 30





Revenues ('000s)





Gross profit before fair value adjustments ('000s)





General and administrative costs ('000s)





Net loss ('000s)





Adjusted EBITDA (1) ('000s)





Net loss per share (basic and diluted)





Weighted average shares outstanding ('000s)






Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization or in this case loss) is a non-IFRS measure calculated as net loss before tax as reported under International Financial Reporting Standards and adding back share-based compensation, fair value adjustments on biological asset, transaction fees, depreciation, interest expense and non-recurring items. Refer to the Company's MD&A for a reconciliation.

Discussion of Operations for the Three Months Ending September 30, 2020
The Company recorded a net loss of $6.7 million in the third quarter of 2020. This compares to a net loss of $10.6 million in the prior year third quarter. On an adjusted EBITDA basis Q3 2020 was a $4.7 million loss compared to the adjusted loss of $5.4 million in Q3 2019 (see Adjusted EBITDA for calculation).

Q3 2020 and the impact of COVID-19 – starting in March 2020, the Company's health centres experienced a decline in patient visits due to the Colombian government's strict quarantine regulations which required the Company to limit the number of patient visits and suspend surgeries. During Q3 2020, following the launch of teleconsultation services in April 2020 and the resumption of surgeries in May 2020, the number of patient services increased and have now surpassed levels observed at the beginning of the year, including complex services such as surgeries. The Company experienced a 12% increase in service revenues from Q2 2020. The Company experienced a 34% decline in service revenues in Q3 2020 compared to Q3 2019. The Company has maintained the cost cutting measures implemented during the second quarter.

Throughout Q3 2020, the Company sold increasing levels of both low- and high-THC medical cannabis through its health centres in Colombia and pharmacy partners. Revenue contributions were $0.1 million in the quarter, a 514% increase from Q2 2020 as prescriptions and sales accelerated on a weekly basis. Cultivation is increasingly focused on growing for commercial sales purposes and less on research and development. In Q3 2020, the Company capitalized $0.3 million in operating costs to inventory and recorded its fair value gain on biological assets of $0.6 million.

Management Commentary
“We have remained fully focused on our sales execution strategy in Q3, while continuing to prudently manage our cash position. Despite the significant impact of the global COVID-19 pandemic we have been able to advance across key sales metrics with our Colombian clinic services returning to pre-pandemic levels of 9,500 monthly consultations and surpassing 5,600 Khiron medical cannabis prescriptions filled. We welcome the rapid adoption of our Doctor ZereniaTM telehealth services which accounted for 55% of prescriptions through the end of October, including 25% from outside of Bogota. These are significant advancements in our Colombian business and provide us with proprietary data and experiences that we can adopt as we increase revenue opportunities and utilize towards improving the quality of lives of patients in Latin America,” comments Alvaro Torres, Khiron CEO and Director.

Webcast and Q&A
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend a webcast and Q&A to discuss the Company's Q3 2020 financial statements and further activities.
DATE: Tuesday, December 1, 2020
TIME: 10:00am EST/7:00am PST
PRESENTERS: Alvaro Torres, CEO and Director, Joel Friedman, CFO, and Chris Naprawa, Chairman
FORMAT: Live 20 minutes presentation and Q&A session

About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America.  Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products. The Company has presence in Mexico, Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales of medical cannabis.

Leveraging its first-mover advantage, and patient oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at, and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Cision View original content to download multimedia:

SOURCE Khiron Life Sciences Corp.

Continue Reading


Global Insurance Symposium Returns to Showcase Industry Trends & Future


DES MOINES, Iowa, Nov. 30, 2020 /PRNewswire/ — The Global Insurance Symposium (GIS) announced its 2021 conference will be held on April 26–28. This event will host insurance professionals from around the world and will feature an extensive slate of dynamic panel discussions led by preeminent executives and dignitaries, interactive demonstrations of new technologies and opportunities for attendees to help shape the future of the industry.

Organizers will determine at the beginning of 2021 if the GIS will be a virtual, hybrid or in-person event at the Community Choice Credit Union Convention Center in Downtown Des Moines.

Presented by the Greater Des Moines Partnership, the Iowa Insurance Division, the Iowa Economic Development Authority and Iowa insurance firms, the event's host city boasts the highest concentration of insurance employment among metros in the United States. Since its inception in 2014, GIS has had thousands of attendees from 13 countries participate.

Des Moines is an insurance hub with nearly 80 insurance companies headquartered here and more than 200 insurance companies statewide,” said Jay Byers, CEO of the Greater Des Moines Partnership. “Whether the Global Insurance Symposium is held in-person, virtually or by a hybrid model, convening InsurTech and FinTech leaders and innovators will spur new ideas, collaborations and the sharing of best practices to help shape the future of insurance.”

The three-day symposium will offer opportunities for attendees to learn about insurance trends from state insurance commissioners, industry leaders, entrepreneurs and regulatory representatives, as well as network and explore avenues for growth with peers, both domestic and international.

Iowa Insurance Commissioner Doug Ommen noted, “This is a must-see event for those in or around the insurance industry. Whether you are a leader at an insurer, an interested regulator or an entrepreneur with a startup, there is something for everyone. The 2021 Global Insurance Symposium will help position leaders in the industry to meet current and upcoming challenges.”

In preparation for the 2021 Symposium, organizers are monitoring health guidelines and safety concerns as well as utilizing The Partnership's COVID-19 Rapid Response Hub and DSM Forward playbooks.

For more information, including forthcoming registration dates (early 2021) and the format of the 2021 Global Insurance Symposium, as well as sponsorship opportunities, please visit:

Media Registration:
Members of the media are invited to attend the Global Insurance Symposium. To inquire, please contact Jon Lieb at [email protected].

About the Global Insurance Symposium:
Since its inception in 2014, the Global Insurance Symposium has hosted thousands of leading insurance and financial service professionals and regulatory authorities. During the GIS three-day event, attendees hear from the world's most renowned insurance experts and interact with fellow insurance industry colleagues from around the globe. The Global Insurance Symposium is presented by the Greater Des Moines Partnership, the Iowa Insurance Division, the Iowa Economic Development Authority and Iowa insurance firms. For more information, please visit

Cision View original content:–future-301181956.html

SOURCE Global Insurance Symposium

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News8 mins ago

Global Point of Care Diagnostics Market Growth Momentum to Reduce During 2020-2024 | Technavio

The point of care diagnostics market is poised to grow by USD 10.69 billion during 2020-2024, decelerating at a CAGR...

gbafNews28 gbafNews28
News8 mins ago

AFX Forms Strategic Alliance with Citi

CHICAGO, Nov. 30, 2020 /PRNewswire/ — AFX has formed a strategic alliance with Citi in which the Bank will join...

gbafNews28 gbafNews28
News8 mins ago

Far Peak Acquisition Corporation Announces Launch of Initial Public Offering

NEW YORK, Nov. 30, 2020 /PRNewswire/ — Far Peak Acquisition Corporation (the “Company”) announced today that it has commenced its...

gbafNews28 gbafNews28
News8 mins ago

Royce Global Value Trust, Inc. Special Meeting of Stockholders Postponed to December 17, 2020

NEW YORK, Nov. 30, 2020 /PRNewswire/ — Royce Global Value Trust, Inc. (NYSE: RGT) (the “Fund”) today announced that the...

gbafNews28 gbafNews28
News8 mins ago

Invesco Provides Estimated Capital Gain Distribution Information for 2020

ATLANTA, Nov. 30, 2020 /PRNewswire/ — Invesco Ltd. (NYSE: IVZ) a leading global provider of exchange-traded funds (ETFs), announced today...

gbafNews28 gbafNews28
News8 mins ago

Community Healthcare Trust Announces Executive Retirement

FRANKLIN, Tenn., Nov. 30, 2020 /PRNewswire/ — Community Healthcare Trust Incorporated (NYSE: CHCT) (the “Company”) announced today that W. Page Barnes,...

gbafNews28 gbafNews28
News8 mins ago

Some Insurers Gut D&O Insurance in a Core Area

BOSTON, Nov. 30, 2020 /PRNewswire/ — Directors and Officers: Are You Covered if Sued by Your Investors/Shareholders?  (Investors: will your claim...

gbafNews28 gbafNews28
News8 mins ago

Banco Macro Announces Results for the Third Quarter of 2020

BUENOS AIRES, Argentina, Nov. 30, 2020 /PRNewswire/ — Banco Macro S.A. (NYSE: BMA; BYMA: BMA) (“Banco Macro” or “BMA” or the...

gbafNews28 gbafNews28
News8 mins ago

ERF Wireless, Inc. Announces Delay in Effective Date of a Name Change and Reverse Split of Its Common Stock

DALLAS, Nov. 30, 2020 /PRNewswire/ — ERF Wireless, Inc. (OTC PINK: ERFB) The Board of Directors announced today that the regulatory approval...

gbafNews28 gbafNews28
News8 mins ago

Global Insurance Symposium Returns to Showcase Industry Trends & Future

DES MOINES, Iowa, Nov. 30, 2020 /PRNewswire/ — The Global Insurance Symposium (GIS) announced its 2021 conference will be held...